There's a common thread through some analysts' notes on biotech stocks this morning: "Here's why this stock isn't like Dendreon (DNDN)." Dendreon helped take down stocks of rival biotech companies today and yesterday after …
Dendreon Corporation (Nasdaq:DNDN) hit a new 52-week low Monday as it is currently trading at $11.27, below its previous 52-week low of $11.34 with 3.3 million shares traded as of 10:22 a.m. ET. Average volume has been 3.4 million …
I like smarter guys than me to do the earlier heavy lifting. So I look for good successful investors who are also buying the stock. When it comes to DNDN that’s easy. According to recent filing there are at least 4 super billionaire investors …
NEW YORK (CNNMoney.com) -- Dendreon's stock price surged immediately after the open of Friday trading, following an surprise positive vote from FDA advisors the day before, which favored the experimental prostate cancer treatment …
Yep, we implemented this same trade two years ago prior to the FDA advisory committee meeting that endorsed Provenge, pushing DNDN stock from $4 to $25…a month before it was—shockingly—not approved by the FDA itself, crashing the …
The rights will be exercisable only if a person or group acquires 20 percent or more of Dendreon's common stock or at the times specified in the Rights Plan after a person or group commences or announces a tender offer for 20 percent or …
Dendreon (NASDAQ:DNDN) chief executive John Johnson has talked of the possibility of the company seeking a marketing partner in Europe for its Provenge cancer therapy in an effort to boost sales. Shareholders have been …
Shares of Dendreon are off over 2% today despite an overall flat market. And down 12% in the past week despite the S&P being down about 0.4%. But even more importantly, shares of DNDN, currently at 34 and change are off 23 points from …
Dendreon stock, shown with light-blue shading, dropped more than 70 percent from Tuesday, Aug. 2, to Monday, Aug. 8. The Dow Jones (red), S&P 500 (brown) and Nasdaq (green) are also shown. Dendreon stock, shown with light-blue …
NEW YORK (Reuters) - A lightening fast sell-off of shares of biotech company Dendreon last April is drawing scrutiny from U.S. securities regulators and the independent monitor assigned to keep tabs on those regulators, said people …